Mark Elliott Boulding net worth and biography

Mark Boulding Biography and Net Worth

Mr. Boulding has served as our Executive Vice President and Chief Legal Officer since March 2012, and previously served as our Senior Vice President and General Counsel from April 2002 to February 2012 and our Corporate Secretary from 2002 to 2017. He also serves as a director of one and as co-secretary of two subsidiaries of PTC. Prior to joining us, Mr. Boulding served as General Counsel, Executive Vice President and Secretary of MedicaLogic/Medscape, Inc., a provider of digital health records software and healthcare information, from May 2000 to April 2002. From June 1999 to May 2000, Mr. Boulding served as the General Counsel, Vice President and Secretary of Medscape, Inc., a provider of online health information and education. Mr. Boulding previously was a partner in two Washington, D.C.-based law firms. Mr. Boulding received a J.D. from the University of Michigan and a B.A. from Yale College.

What is Mark Elliott Boulding's net worth?: The estimated net worth of Mark Elliott Boulding is at least $1.76 million as of January 30th, 2024. Mr. Boulding owns 71,189 shares of PTC Therapeutics stock worth more than $1,757,656 as of April 19th. This net worth evaluation does not reflect any other investments that Mr. Boulding may own. Additionally, Mr. Boulding receives a salary of $824,090.00 as VP at PTC Therapeutics. Learn More about Mark Elliott Boulding's net worth.
How old is Mark Elliott Boulding?: Mr. Boulding is currently 63 years old. There are 6 older executives and no younger executives at PTC Therapeutics. The oldest executive at PTC Therapeutics is Dr. Allan Steven Jacobson Ph.D., Co-Founder, Chairman of Scientific Advisory Board & Independent Director, who is 78 years old. Learn More on Mark Elliott Boulding's age.
What is Mark Elliott Boulding's salary?: As the VP of PTC Therapeutics, Inc., Mr. Boulding earns $824,090.00 per year. There are 4 executives that earn more than Mr. Boulding. The highest earning executive at PTC Therapeutics is Dr. Stuart W. Peltz Ph.D., Co-Founder, Senior Consultant & Member of Scientific Advisory Board, who commands a salary of $1,540,000.00 per year. Learn More on Mark Elliott Boulding's salary.
How do I contact Mark Elliott Boulding?: The corporate mailing address for Mr. Boulding and other PTC Therapeutics executives is 100 CORPORATE COURT, SOUTH PLAINFIELD NJ, 07080. PTC Therapeutics can also be reached via phone at (908) 222-7000 and via email at [email protected]. Learn More on Mark Elliott Boulding's contact information.
Has Mark Elliott Boulding been buying or selling shares of PTC Therapeutics?: Mark Elliott Boulding has not been actively trading shares of PTC Therapeutics within the last three months. Most recently, Mark Elliott Boulding sold 794 shares of the business's stock in a transaction on Tuesday, January 30th. The shares were sold at an average price of $27.25, for a transaction totalling $21,636.50. Following the completion of the sale, the vice president now directly owns 71,189 shares of the company's stock, valued at $1,939,900.25. Learn More on Mark Elliott Boulding's trading history.
Who are PTC Therapeutics' active insiders?: PTC Therapeutics' insider roster includes Neil Almstead (Insider), Mark Boulding (VP), Emily Hill (CFO), Allan Jacobson (Director), Matthew Klein (COO), Stephanie Okey (Director), Eric Pauwels (Insider), Stuart Peltz (CEO), Dawn Svoronos (Director), and Christine Utter (CAO). Learn More on PTC Therapeutics' active insiders.
Are insiders buying or selling shares of PTC Therapeutics?: During the last twelve months, PTC Therapeutics insiders bought shares 1 times. They purchased a total of 7,700 shares worth more than $198,737.00. During the last twelve months, insiders at the biopharmaceutical company sold shares 15 times. They sold a total of 74,000 shares worth more than $3,065,186.49. The most recent insider tranaction occured on April, 2nd when EVP Lee Scott Golden sold 526 shares worth more than $14,922.62. Insiders at PTC Therapeutics own 5.3% of the company. Learn More about insider trades at PTC Therapeutics.
Information on this page was last updated on 4/2/2024.

Mark Elliott Boulding Insider Trading History at PTC Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
1/30/2024	Sell	794	$27.25	$21,636.50	71,189
1/8/2024	Sell	1,457	$28.64	$41,728.48	73,921
4/17/2023	Sell	61,923	$51.42	$3,184,080.66	75,378
1/31/2023	Sell	812	$45.63	$37,051.56	75,378
1/11/2023	Sell	495	$44.36	$21,958.20	76,190
1/9/2023	Sell	835	$41.66	$34,786.10	77,275
10/18/2022	Sell	299	$55.06	$16,462.94	61,110
9/20/2022	Sell	1,176	$55.00	$64,680.00	61,110
4/13/2022	Sell	2,276	$45.17	$102,806.92	61,110
4/5/2022	Sell	5	$45.00	$225.00	61,110
2/10/2022	Sell	17,935	$45.03	$807,613.05
2/1/2022	Sell	779	$40.00	$31,160.00
1/7/2022	Sell	885	$38.52	$34,090.20
7/8/2021	Sell	7,805	$45.22	$352,942.10
2/1/2021	Sell	778	$56.96	$44,314.88	48,374
1/5/2021	Sell	772	$62.37	$48,149.64	38,952
7/7/2020	Sell	30,625	$55.12	$1,688,050.00	52,849
7/5/2019	Sell	15,312	$44.74	$685,058.88	32,805
7/1/2019	Sell	181,667	$45.00	$8,175,015.00
6/28/2019	Sell	77,575	$45.00	$3,490,875.00
6/8/2015	Sell	56,849	$55.04	$3,128,968.96
3/20/2015	Sell	21,142	$68.12	$1,440,193.04
3/20/2014	Sell	10,049	$30.96	$311,117.04	32,235

Mark Elliott Boulding Buying and Selling Activity at PTC Therapeutics

PTC Therapeutics Company Overview

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.

Today's Range

Now: $24.69

$24.47

$25.28

50 Day Range

MA: $28.08

$24.15

$31.95

2 Week Range

Now: $24.69

$17.53

$59.84

Volume

820,086 shs

Average Volume

601,869 shs

Market Capitalization

$1.89 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.67

AI “wealth window” is closing soon!

From Paradigm Press | Ad

Today, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRILLION industry.

I put together this personal video [HERE]…

Mark Boulding Biography and Net Worth

What is Mark Elliott Boulding's net worth?

How old is Mark Elliott Boulding?

What is Mark Elliott Boulding's salary?

How do I contact Mark Elliott Boulding?

Has Mark Elliott Boulding been buying or selling shares of PTC Therapeutics?

Who are PTC Therapeutics' active insiders?

Are insiders buying or selling shares of PTC Therapeutics?